OUR

Brand story

Our research team has focused on targeted neuromodulation for over 12 years. For many of them, our attention has been drawn to the unmet need of hypertension management. There are 1.28 billion patients in the world, and the blood pressure control efficacy rate is less than 20% with medication and lifestyle modifications.

Through studying renal denervation (RDN) surgery, a procedure that ablates the renal artery sympathetic nerve to manage resistant hypertension, we discovered a viable alternative method. The site of rostral ventrolateral medulla (RVLM), which affects sympathetic activity and blood pressure, could be accessed through the peripheral nerves in the wrist. With high-precision, non-invasive electric pulses, the sympathetic activity can be inhibited, and blood pressure can be controlled.